Certara, Inc. (NASDAQ:CERT) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Certara, Inc. (NASDAQ:CERT) have earned an average recommendation of “Moderate Buy” from the sixteen brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $12.5833.

Several equities analysts have commented on CERT shares. Leerink Partners raised shares of Certara from a “market perform” rating to an “outperform” rating and set a $13.00 target price on the stock in a research note on Tuesday, January 6th. Craig Hallum initiated coverage on Certara in a research report on Monday, September 29th. They issued a “buy” rating and a $16.00 target price for the company. Morgan Stanley lowered their price target on Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 18th. Rothschild & Co Redburn assumed coverage on Certara in a research note on Friday, November 21st. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, Redburn Partners set a $10.00 target price on Certara in a research note on Friday, November 21st.

Hedge Funds Weigh In On Certara

Several hedge funds have recently made changes to their positions in CERT. Fort Washington Investment Advisors Inc. OH bought a new stake in shares of Certara in the third quarter worth $11,899,000. Intech Investment Management LLC acquired a new stake in Certara in the 2nd quarter valued at $329,000. Versor Investments LP lifted its position in Certara by 104.0% during the 2nd quarter. Versor Investments LP now owns 89,346 shares of the company’s stock worth $1,045,000 after buying an additional 45,546 shares in the last quarter. Pier 88 Investment Partners LLC acquired a new position in shares of Certara during the 2nd quarter worth about $821,000. Finally, Claret Asset Management Corp grew its holdings in shares of Certara by 51.1% in the 2nd quarter. Claret Asset Management Corp now owns 20,437 shares of the company’s stock valued at $239,000 after acquiring an additional 6,908 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Stock Performance

Shares of CERT stock opened at $10.11 on Friday. Certara has a 12-month low of $8.02 and a 12-month high of $15.69. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of 144.43 and a beta of 1.46. The business has a 50 day simple moving average of $9.05 and a 200 day simple moving average of $10.45.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. Certara had a return on equity of 5.18% and a net margin of 2.62%.The company had revenue of $104.62 million during the quarter, compared to analyst estimates of $104.53 million. During the same quarter in the previous year, the firm posted $0.13 EPS. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, equities research analysts anticipate that Certara will post 0.28 EPS for the current year.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.